Multicenter and Open Pilot Clinical Study on the Safety of a New One-piece Convex Appliance in Patients With Enterostomy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Primary outcome Measure:
To describe Investigational Device performance in term of level of leakage under the skin protector
Secondary Outcome Measure:
- Assessment of the condition of peristomal skin
- Assessment of other performance criteria
- Assessment of AEs for each patient
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Dijon, France, 21000
- Patrick RAT
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patient is at least 18 years old,
- patient having a colostomy or an ileostomy for at least 1 month,
- patient having a stoma's diameter inferior to 45 mm,
- patient having a flat or flushed or slightly retracted stoma,
- patient using currently a one-piece soft convex or standard ostomy appliance with closed or drainable bags,
- patient using a minimum of 1 product per day with closed pouches or minimum 1 product per two days with drainable pouches
- patient capable to apply and remove the pouch himself or with the help of a caregiver (except health care professional)
- patient having a mental capacity to participate to the study (i.e. to understand the study and to answer to the questions)
- patient agreeing to test investigational product during 14(±3) days.
- patient covered by social security
Exclusion Criteria:
- patient experiencing repeated leakages with his current appliance,
- patient receiving or having received, within the last month, chemotherapy or radiotherapy or corticotherapy,
- patient having a deeply retracted stoma,
- patient currently suffering from peristomal skin complications (bleeding or severe irritation or red and broken skin at the time of inclusion),
- patient already participating in another clinical study or who have previously participated in this investigation,
- pregnant or breast-feeding woman
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Flexima Active Soft convexe
Flexima Active soft convexe (1 to 3 appliances per day)
|
The Investigational Device will be used during 14 +- 3 days.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Flexima® Active Soft Convex ostomy appliance performance description in term of level of leakage under the skin protector
Time Frame: 14 +- 3 days
|
14 +- 3 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Peristomal skin evaluation with DET score scale
Time Frame: baseline and 14 +- 3 days
|
baseline and 14 +- 3 days
|
|
|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time Frame: baseline and 14 +- 3 days
|
baseline and 14 +- 3 days
|
|
|
Investigational product wear time
Time Frame: 14 +- 3 days
|
The patient will complete his patient diary after each Investigational Product removal
|
14 +- 3 days
|
|
Investigational product adhesivity as measured by a Likert scale score (1-4)
Time Frame: 14 +- 3 days
|
14 +- 3 days
|
|
|
Investigational product flexibility as measured by a Likert scale score (1-4)
Time Frame: 14 +- 3 days
|
14 +- 3 days
|
|
|
Investigational product conformability as measured by a Likert scale score (1-4)
Time Frame: 14 +- 3 days
|
14 +- 3 days
|
|
|
Convex ring suppleness of the Investigational product as measured by a Likert scale score (1-4)
Time Frame: 14 +- 3 days
|
14 +- 3 days
|
|
|
Connection of the Investigational Product belt to the belt hear as measured by a Likert scale score (1-4)
Time Frame: 14 +- 3 days
|
14 +- 3 days
|
|
|
Residues on the skin after each Investigational Product removal as measured by a Likert scale score (1-4)
Time Frame: 14 +- 3 days
|
14 +- 3 days
|
|
|
Ease of Investigational Product handling as measured by a Likert scale score (1-4)
Time Frame: 14 +- 3 days
|
14 +- 3 days
|
|
|
Investigational Product wearing comfort as measured by a Likert scale score (1-4)
Time Frame: 14 +- 3 days
|
14 +- 3 days
|
|
|
Investigational Product leakage prevention as measured by a Likert scale score (1-4)
Time Frame: 14 +- 3 days
|
14 +- 3 days
|
|
|
Feeling of Investigational Product security as measured by a Likert scale score (1-4)
Time Frame: 14 +- 3 days
|
14 +- 3 days
|
|
|
Investigational Product overall satisfaction as measured by a Likert scale score (1-4)
Time Frame: 14 +- 3 days
|
14 +- 3 days
|
|
|
Use of Investigational Product in the future as measured by a Likert scale score (1-2)
Time Frame: 14 +- 3 days
|
14 +- 3 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Patrick RAT, MD, University Hospital of Dijon
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- OPM-G-H-1501
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.